Contact forzinity

By forzinity Research Team · Research-reviewed 2026-09-13 · Evidence-graded per our editorial policy

How to reach us

The fastest route is email: contact@forzinityshare.com. We read everything, and corrections to any published number, date, or attribution are handled first. When writing about a specific page, include its URL so the fix lands on the right document.
For data questions — “where does this number come from,” “which trial measured that endpoint,” “is this price current” — include the figure as published and, where possible, the date you saw it. Much of the forzinity record is recent enough that sources still move, and dated questions are answerable questions.

What we do and do not answer

We answer questions about the published record: label data, trial design and results, regulatory status, market-access structure, and the ss-31 research literature. We do not answer personal medical questions, dosing questions, sourcing requests, or anything that would direct an individual's health decisions or purchases — those belong with a clinician or, for market access, with the manufacturer's support program documented on the patient assistance page.
We do not accept guest posts, sponsored content, link placements, or any form of paid coverage. The independence documented on the about page is the site's only asset; nothing compromises it.

Frequently asked questions

Do you accept guest posts or sponsored content?
No. forzinity publishes no sponsored, commissioned, or placement content of any kind, and it links no sellers. Outreach proposing any of these will not receive a reply.
Can you tell me where to buy forzinity or ss-31?
No. This site is research-only and links no sellers in any channel. As a pharmaceutical, forzinity moves through prescription-specialty channels; questions about access belong with a prescriber or the manufacturer's support program.